Abdulrahman AL-Abdulmalek, MD

An important CLL message: More treatment time is not always more benefit. Fixed-duration venetoclax combinations were noninferior to continuous ibrutinib for 3-year PFS in previously untreated disease. @NEJM @VincentRK @Dr_AmerZeidan @kirkizlar @mbeksac56 @OncoAlert @OncBrothers @OncoAlert

Doha, Qatar

🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊 🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications 💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban nejm.org/doi/full/10.10…

Today felt special ; coming back to Weill Cornell Medicine to speak with students about the journey from uncertainty to purpose. I shared not only achievements, but also struggles, turning points, and the people who helped along the way. If there’s one message I hoped they took home: your starting point doesn’t define your future. #Medical #MedicalStudents #Mentorship #meded @WCMQatar @qf_alumni @QF

Proud to see our work shared. Our study shows that how medical students learn and what they value, strongly influences specialty choice. Important implications for mentorship, early exposure, and curriculum design. #MedicalEducation

P1 study of #rogocekib #ctx_712 ⭐️ rrAML/MDS 🧬 spliceosome modulator 🛑 CLKi 👉 ORR 42% ✴️ SFm responded better. ORR 75% ⁦@BloodAdvances⁩ #Amlsm ashpublications.org/bloodadvances/…

استغفر الله العظيم وأتوب إليه

Back to Montreal 🇨🇦 after a wonderful Christmas week in Doha , Qatar🇶🇦; great time at home, recharging and making memories. Landed yesterday and straight back to work today. Grateful for the balance between home and the journey ahead.

🩸 Leukemia & Myeloid Diseases: Highlights of 2025 1️⃣ 🧬 Menin Inhibitors in Acute Leukemia •AUGMENT-101 & KOMET trials show menin inhibition works in relapsed/refractory AML with KMT2Ar/NPM1 mutations •✅ Led to approvals of revumenib & ziftomenib •🆕 Marks a new class of targeted AML therapies

🎄Wishing peace, kindness, and warmth to everyone celebrating Christmas. May this season be filled with compassion, hope, and moments that bring us closer together. ✨ enjoy your time with your loved ones and family !

🔥 CLL17 NEJM 2025 — Fixed-Duration vs Continuous Therapy Source: NEJM 2025 — Al-Sawaf et al. ⸻ 🧬 CLL17 = First head-to-head trial comparing: 1️⃣ Venetoclax + Obinutuzumab (VO) — fixed 1 year 2️⃣ Venetoclax + Ibrutinib (VI) — fixed 1 year 3️⃣ Ibrutinib — continuous ⸻ 📈 Primary Endpoint: PFS 🎯 Non-inferiority achieved •3-yr PFS: • VO: 81.1% • VI: 79.4% • Ibrutinib: 81.0% ✨ Hazard ratios met strict non-inferiority margin for both fixed-duration arms. ⸻ 🧪 MRD Negativity (Cycle 18) 💥 Massive MRD advantage for fixed therapy: •VO: 73.3% PB MRD-negative •VI: 47.2% •Ibrutinib: 0% 🦴 BM MRD-negative: •VO: 62% •VI: 40% •Ibrutinib: 0% ⸻ 💊 Response Rates •CR: • VO: 51.5% • VI: 46.2% • Ibrutinib: 8.3% •ORR: ~85–89% across all arms. ⸻ 🧬 Subgroups (Key Signals) •Unmutated IGHV: NO disadvantage to fixed-duration therapy. •Mutated IGHV: VO showed exceptional PFS (87.6% at 3 yrs). •del17p/TP53: numerically best PFS with VI & ibrutinib, but small numbers. •Complex Karyotype: trend favoring VI over VO. ⸻ ⚠️ Safety Profiles 🦠 Infections most common (incl. COVID era): •Severe infections: • VO: 15.9% • VI: 8.6% • Ibru: 6.7% 💀 Infection-related deaths highest with VO. 💓 Cardiac toxicity: •Atrial fibrillation & hypertension highest with continuous ibrutinib. •VI intermediate. •VO lowest. 💥 TLS: •VO: 12 cases (mostly after day 1 obinutuzumab). •VI: 4 cases. •Ibru: 1 case. 🟢 All manageable with standard protocols. ⸻ 🧭 Clinical Meaning ✨ Fixed-duration therapy is as effective as continuous BTK inhibition — with treatment-free intervals and deeper MRD clearance. ✨ VO produces the deepest remissions. ✨ VI may be preferable in high-risk genetics (TP53, complex karyotype). ✨ Ibrutinib continuous is no longer automatically the default first-line option. ⸻ 🏁 Bottom Line 🔹 CLL17 changes practice: Fixed-duration regimens (VO or VI) are non-inferior to continuous ibrutinib with deeper MRD, fewer cardiac events, and finite therapy. 🔹 Choice should be tailored by genetics, fitness, infection risk, and patient preference. ⸻ 📚 Reference: Al-Sawaf O, et al. N Engl J Med. 2025; “Fixed-Duration vs Continuous Treatment for CLL.” ⸻ #CLL #Hematology #Leukemia #TargetedTherapy #NEJM #CLL17 #SOHO25 #ESH #EmiratesHematologySociety

Patients with ECD-C had more CV morbidities, even before diagnosis, than those without and a matched cohort. Read in Blood Advances: ow.ly/OfZS50XH09a

@Taha_CancerDoc @OU_Alumni Congratulations! Well deserved 😍

BOOMER SOONER Finally done with my MBA & now officially @OU_Alumni It wasn’t easy to make it to this day when you have a busy clinical practice plus everything else we do, credit to the best wife in the 🌍. Time to use these skills as aCMO to improve cancer care in Oklahoma

This week in clinic, my patients gave me holiday gifts. But what they really gave me was perspective. Their kindness, strength, and gratitude stayed with me long after the day ended. In the middle of uncertainty and struggle, they still find space for generosity and warmth. Moments like this remind me why I chose this path. 🤍 Happy holidays 🎄 . .

Myeloma Combination Cuts Line for FDA Approval After Strong ASH Results - goo.gl/alerts/VQQnZA #GoogleAlerts

Important poster at #ASH25: “A Canadian national needs assessment for an immunology curriculum for hematology residents.” Key findings: • Median adequacy score for current immunology teaching was 3/10 • 70% of respondents rated content as 2 or 3 (too little) • 78% felt immunology is very or extremely relevant to daily hematology practice • 80% felt it is very or extremely important to incorporate immunology into hematology training This strongly resonates with my experience. When I started fellowship, one of the first things I did was buy Janeway’s Immunobiology to build a solid foundation. Modern hematology is inseparable from immunology. #Hematology #Immunology #MedicalEducation #ASH25

Real-world effectiveness of recombinant zoster vaccine in allogeneic hematopoietic cell transplant recipients @ASTCT_Journal astctjournal.org/article/S2666-…

Always happy to see medical students and residents interested in joining my projects. Curiosity, initiative, and teamwork are what drive meaningful learning and growth; and I’m glad to support trainees who are eager to get involved and build their academic journey. #Mentorship #MedicalStudents #Residents #MedicalEducation

Breast Cancer Management algorithms after #SABCS25 ⤵️